AriaVax, Inc. is a research stage biotechnology company developing novel vaccines for a variety of diseases. to include HIV and AIDS. The firm's vaccines are based on its proprietary peptide chemistry technology exclusively licensed by the Company from National Institutes of Health. This technology allows the development of vaccines that selectively and specifically generate effective antibody-inducing immune responses against previously inaccessible critical segments of viral or bacterial proteins, or the cellular proteins to which these pathogens attach. Focus is on creation of vaccines that will selectively and specifically generate effective immune responses. Currently, the vaccines available are unable to access critical segments of proteins on important pathogens
